Snail-derived Compound Prevents Clots While Preserving Normal Bleeding

For more than a century, heparin has been nan go-to anticoagulant to prevent harmful blood clots in blood vessels aliases nan heart from forming aliases getting larger. However, a awesome broadside effect is an accrued consequence of excessive bleeding, even from insignificant injuries like small cuts on nan skin. In ACS Central Science, researchers study nan find of a snail-derived compound that blocks clot formation while still preserving bleeding control in mouse models. 

Blood clots are earthy impermanent bandages that seal wounds and stop bleeding. These helpful clots - called hemostatic clots - speed healing to injuries like cuts to nan skin. But a harmful type of clot called a thrombus can shape inside blood vessels and nan heart, blocking humor travel and causing terrible symptom and insubstantial damage. Deep vein thrombosis (DVT) occurs erstwhile these long-lasting clots form successful nan legs and don't dissolve like they should. If they break distant and move to different parts of nan body, thrombi can cause strokes, shortness of breath and possibly death. Although heparin and different humor thinners help prevent thrombi, these anticoagulants also interfere with normal clotting (hemostasis) and raise the consequence of excessive bleeding. So, Mingyi Wu and colleagues looked for a safer, people occurring anticoagulant that only targets thrombus formation. 

After analyzing numerous mollusk compounds, the researchers identified CCG, a new glycosaminoglycan (a type of analyzable sugar) from nan snail Camaena cicatricosa. Although part of CCG's molecular structure is similar to heparin, the sugar sequence that heparin uses to attach to 1 of its binding partners is missing successful CCG. The researchers hypothesized that these differences could make CCG a safer anticoagulant. 

In tests with human plasma, CCG inhibited thrombus formation and had nary effect connected hemostasis. In rodent models of DVT, CCG administered by injection also reduced nan incidence of thrombi DVT and, unlike heparin, did not summation bleeding risk. Further testing revealed that CCG prevents nan assembly of an enzyme (iFXase) that is progressive successful thrombus formation but not hemostasis. 

Although much investigation is needed, these initial results propose that this snail-derived compound could be developed into a safer anticoagulant compared with heparins, the authors say.